Elevance Health Inc.

Elevance Health Inc.

ELV

$398.25

Updated: 24/09/2026, 22:03:43

Market Cap
$86.37B
Sector
Healthcare
Industry
Medical - Healthcare Plans
Country
US
Stock valuation chart
One-year closing share-price history for ELV
Company Profile

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

USD
NYSE
CEO: Gail Koziara Boudreaux
Employees: 96,615
https://www.elevancehealth.com
Asset Summaries
Latest generated summaries for ELV

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
ELV-10-k-fy2025.html3.6 MBtext/htmlENFiled 06/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 36 KPI observations

Revenue

N/A

FY — · Reported

Net income

$5.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$3.2B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$2.6B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Brand portfolio
Managed care services to fee-based customers
Managed care plan types
Federal Employee Program
Specialty services

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Elevance Health is a leading health company; one of the largest US health insurers serving ~45.2 million medical members as of Dec 31, 2025; independent licensee of the Blue Cross and Blue Shield Association

99%
Source evidence
“We are one of the largest health insurers in the United States in terms of medical membership, serving approximately 45.2 million medical members through our affiliated health plans as of December 31, 2025.”

Revenue model

Revenue from risk-based premiums, administrative fees from self-funded employers, and pharmacy/health service fees via Carelon

97%
Source evidence
“we generate revenue through risk-based premiums, administrative fees from self-funded employers and pharmacy and health service fees through our Carelon businesses.”

Reportable segments

Four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other

99%
Source evidence
“We report our results of operations in the following four reportable segments: Health Benefits, CarelonRx, Carelon Services and Corporate & Other”

Customer markets

Network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets plus fee-based customers

97%
Source evidence
“We offer a broad spectrum of network-based managed care risk-based plans to Individual, Employer Group, Medicaid and Medicare markets.”

Brand portfolio

Core go-to-market brands: Anthem Blue Cross/Anthem BCBS, Wellpoint, Carelon

98%
Source evidence
“Our portfolio consists of the following core go-to-market brands: •Anthem Blue Cross/Anthem Blue Cross and Blue Shield”

Managed care services to fee-based customers

Broad array of managed care services to fee-based customers including claims processing, stop loss insurance, network access, medical/care management, wellness, actuarial and administrative services

97%
Source evidence
“we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, care provider network access, medical management, care management, wellness programs, actuarial services and other administrative services”

Managed care plan types

Managed care plans include PPOs, HMOs, POS, Traditional Indemnity, Consumer-Driven Health Plans, hospital-only and limited benefit products

95%
Source evidence
“Our managed care plans include: Preferred Provider Organizations; Health Maintenance Organizations; Point-of-Service plans; Traditional Indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products.”

Federal Employee Program

Administers the Federal Employee Program (FEP) for the federal government

95%
Source evidence
“We provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employee Program® (“FEP®”).”

Specialty services

Specialty services: pharmacy, stop loss, dental, vision, supplemental health, integrated health services — to both affiliated and unaffiliated health plans

95%
Source evidence
“We provide an array of specialty services both to customers of our subsidiary health plans and to unaffiliated health plans, including pharmacy services, stop loss insurance, dental, vision and supplemental health insurance benefits”

Non-US revenue

An immaterial amount of total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico

90%
Source evidence
“An immaterial amount of our total consolidated revenues is derived from activities outside of the U.S. and Puerto Rico.”

Operations and dependencies

State revenue concentration

Largest revenue concentrations in California, New York, Virginia, Indiana, Ohio, Georgia, Florida and Texas

95%
Source evidence
“The states in which we operate with the largest concentrations of revenues include California, New York, Virginia, Indiana, Ohio, Georgia, Florida and Texas.”

Employee population

Approximately 97,100 employees as of Dec 31, 2025 (71,900 U.S., 25,200 international); 99% full-time

97%
Source evidence
“our employee population, including all full-time, part-time and temporary workers, consisted of approximately 97,100 individuals, 71,900 in the United States and 25,200 internationally.”

Positioning and strategy

CMS Star Ratings impact

CMS Star Ratings performance influences Medicare Advantage reimbursements and quality-based bonus payment eligibility

95%
Source evidence
“our performance under the Centers for Medicare & Medicaid Services (“CMS”) Star Ratings program, which influences Medicare Advantage plan reimbursements as well as our eligibility to earn quality-based bonus payments for those plans”

Membership level drivers

Membership affected by pricing, Medicaid redeterminations, aging population, utilization, economic conditions and market changes

92%
Source evidence
“our results of operations are also impacted by membership levels and mix of membership, which has changed, and will continue to change, as a result of the pricing of our health benefits products and services, Medicaid redeterminations, an aging population, healthcare utilization patterns”

Risks, financing, and outlook

Healthcare cost drivers

Healthcare costs driven by medical cost inflation, labor costs, drug costs, new technologies, demographics, fraud and mandated benefits

94%
Source evidence
“These factors include, among others: changes in healthcare practices; healthcare utilization patterns; demographic characteristics including the aging population; ... medical cost inflation; increased labor costs; provider and member fraud”

BCBSA license dependency

Risk to BCBSA licenses; future business combinations may risk BCBSA license termination

90%
Source evidence
“events that may negatively affect our licenses with the Blue Cross and Blue Shield Association”

Acquisition/M&A risk factors

M&A subject to FTC/DOJ/state approval risk; integration and JV partner dispute risks

90%
Source evidence
“government actions such as actions by the Federal Trade Commission, Department of Justice, or state governmental agencies may affect our ability to complete our business combinations”

Legislative environment outlook

Results will be shaped by legislative/regulatory changes including subsidies, taxes and fees; states expected to continue healthcare reform focus

90%
Source evidence
“We expect state legislatures will continue to focus on healthcare delivery and financing issues, including actions to reduce or limit increases to premium payments, provider billing protections, access to care and other reforms of state health insurance markets.”

International operations regulatory exposure

International operations subject to FCPA and foreign anti-bribery, AML, data protection and privacy laws

90%
Source evidence
“our non-U.S. operations are subject to U.S. laws regulating the conduct and activities of U.S.-based businesses operating abroad, including but not limited to, the Foreign Corrupt Practices Act”

Goodwill and intangibles impairment

~$39.5B goodwill and other intangibles (32.5% of total assets) as of Dec 31, 2025; potential impairment risk

95%
Source evidence
“As of December 31, 2025, we had approximately $39.5 billion of goodwill and other intangible assets, representing 32.5% of our total consolidated assets.”

Healthcare cost prediction/pricing risk

Profitability depends on predicting and pricing healthcare costs; commercial/Medicaid premiums fixed 12 months; Medicare bids submitted to CMS six months before contract year

95%
Source evidence
“Generally, our premiums on commercial policies and Medicaid contracts are fixed for a 12-month period and are determined based on data from several months prior to the commencement of the premium period. Our revenue from Medicare policies is based on bids submitted to CMS six months prior to the start of the contract year.”

Cyber-attack and data security risk

Cyber-attack or data security incident could cause unauthorized disclosure, disrupt operations and create liability

95%
Source evidence
“A cyber-attack or other privacy or data security incident sustained by us or third parties we rely on could result in an unauthorized disclosure of sensitive or confidential information, cause a loss of data, disrupt our operations”

Regulatory exposure

Significant state and federal regulation across licensing, premiums, marketing, provider contracting; ACA changes and Medicare/Medicaid funding changes could adversely affect the business

94%
Source evidence
“We are subject to significant state and federal regulation across many aspects of our business, including, but not limited to, licensing, premiums, marketing activities, provider contracting, access and payment standards, and corporate governance and financial reporting matters”

Public health crises and natural disasters

Pandemics, extreme events and natural disasters (wildfires, floods, hurricanes, etc.) could increase costs and disrupt operations; climate change may intensify effects

93%
Source evidence
“Natural disasters or extreme weather events, such as wildfires, floods, hurricanes, tropical storms, and snow and ice storms, have impacted, and may in the future impact, our customers, associates, facilities and third-party vendors located in the affected area.”

Holding company dividend restrictions

As a holding company, dependent on subsidiary dividends; state laws and BCBSA agreements restrict dividend payments and require minimum capital

93%
Source evidence
“As a holding company, we are dependent on dividends and administrative expense reimbursements from our subsidiaries. Among other restrictions, state insurance and HMO laws restrict the ability of most of our regulated subsidiaries to pay dividends.”

Enrollment reduction risk incl. Medicaid redeterminations

Significant enrollment reduction risk driven by Medicaid redeterminations, workforce reductions, economic conditions and other factors

93%
Source evidence
“a reduction in Medicaid membership due to the implementation of more stringent eligibility redetermination protocols by state agencies”

Talent competition

Intense competition for experienced and highly skilled associates; succession risk for key executives

92%
Source evidence
“We face intense competition for experienced and highly skilled associates, and we may be unable to attract and retain such associates”

Pharmaceutical cost drivers

Pharmaceutical costs affected by regulation, potential tariffs, FDA approvals and discount changes

92%
Source evidence
“current and potential future tariffs and changes in discounts”

Reimbursement restriction risk

Regulators may restrict premium rate changes; rate limits or resulting membership loss could harm results

92%
Source evidence
“federal and state regulatory agencies may restrict or prevent entirely our ability to implement changes in premium rates.”

Substantial indebtedness

Substantial outstanding indebtedness; interest rate risk and potential financing access/cost impacts

92%
Source evidence
“We are exposed to interest rate risk to the extent of our variable rate indebtedness. Increases in interest rates could increase our cost of borrowing, and volatility in U.S. and global financial markets could impact our access to, or further increase the cost of, financing.”

Public Exchange volatility and enhanced PTC expiration

Public Exchange markets are highly volatile; expiration of enhanced PTCs at end of 2025 could affect results

92%
Source evidence
“including any potential changes relating to the expiration of enhanced PTCs at the end of 2025, could affect our results.”

Credit ratings risk

Credit ratings downgrade could limit borrowing and raise costs; strong ratings important to marketing products

90%
Source evidence
“if our credit ratings are downgraded or placed under review, our business, cash flows, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.”

Material exposure graph

ACA, Medicare and Medicaid regulation
Regulatory Exposure

Significant federal/state regulation of licensing, premiums, provider contracting; ACA and Medicare/Medicaid funding, reimbursement, rate-setting and eligibility changes have adversely affected and could adversely affect results.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“changes in government regulations, policies or funding that apply to government-sponsored programs such as Medicare and Medicaid including, among other things, reimbursement levels, quality-based bonus payment determinations, eligibility and redetermination requirements”
U.S. government agencies
Customer Exposure

Approximately 32% of 2025 consolidated revenues came from U.S. government agencies, mostly in the Health Benefits segment; changes to Medicare/Medicaid funding and rates directly affect results.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“Through our participation in various federal government programs, we generated approximately 32%, 31% and 29% of our total consolidated revenues from agencies of the U.S. government for the years ended December 31, 2025, 2024 and 2023, respectively.”
Medical cost inflation
Cost Driver

Advances in medical technology, drug utilization, demographics and regulation contribute to rising healthcare costs; medical cost inflation among factors that may impair cost prediction and profitability.

Relevance 90·Dependency 85·Confidence 94
Source evidence
“medical cost inflation; increased labor costs; provider and member fraud; evolution of new technologies, drugs and treatments”
Blue Cross and Blue Shield Association license agreements
Regulatory Exposure

BCBSA licenses underpin brands and service areas; negative events or business combinations could risk license termination; BCBSA agreements add minimum capital and liquidity requirements.

Relevance 85·Dependency 85·Confidence 92
Source evidence
“We are also a party to license agreements with the BCBSA which contain additional minimum capital and liquidity requirements.”
CMS Star Ratings / Medicare Advantage quality bonus program
Demand Driver

CMS Star Ratings performance influences Medicare Advantage reimbursements and eligibility for quality-based bonus payments; maintaining/improving ratings is a disclosed risk and funding consideration.

Relevance 85·Dependency 80·Confidence 94
Source evidence
“our performance under the Centers for Medicare & Medicaid Services (“CMS”) Star Ratings program, which influences Medicare Advantage plan reimbursements as well as our eligibility to earn quality-based bonus payments for those plans”
CarelonRx pharmacy services
Revenue Exposure

CarelonRx is a reportable segment providing pharmacy services; pharmacy benefit costs are a significant component of healthcare costs and product revenue includes CarelonRx ingredient costs and service fees.

Relevance 85·Dependency 75·Confidence 93
Source evidence
“Product revenue represents services performed by CarelonRx for unaffiliated pharmacy customers and includes ingredient costs (net of any rebates or discounts), including co-payments made by or on behalf of the customer, and service fees.”
California, New York, Virginia, Indiana, Ohio, Georgia, Florida, Texas
Revenue Exposure

Largest revenue concentrations in eight states expose the company to state-specific or regional economic downturns and healthcare coverage changes.

Relevance 85·Dependency 75·Confidence 95
Source evidence
“The states in which we operate with the largest concentrations of revenues include California, New York, Virginia, Indiana, Ohio, Georgia, Florida and Texas.”
Health benefits industry competition
Competitive Exposure

Customers may renegotiate contracts or move to competitors for favorable premiums; Public Exchange plan selection is highly price sensitive.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“Our customers may renegotiate their contracts to seek to contain their costs or may move to a competitor to obtain more favorable premiums. Public Exchange plan selection by our customers is also highly price sensitive.”
Enhanced PTC expiration / Public Exchange policy
Demand Driver

Public Exchange markets are volatile; potential changes relating to the expiration of enhanced premium tax credits at end of 2025 could affect results and enrollment assumptions.

Relevance 70·Dependency 55·Confidence 90
Source evidence
“including any potential changes relating to the expiration of enhanced PTCs at the end of 2025, could affect our results.”
Labor costs and workforce competition
Cost Driver

Increased labor costs are a healthcare cost factor; company faces intense competition to attract and retain associates which may increase salaries.

Relevance 65·Dependency 55·Confidence 90
Source evidence
“increased labor costs; provider and member fraud; evolution of new technologies, drugs and treatments”
Natural disasters, extreme weather and climate change
Geopolitical Exposure

Natural disasters and extreme weather have impacted customers, associates, facilities and vendors; climate change may increase disaster frequency/intensity with long-term impact on the health benefits and pharmacy services industries.

Relevance 65·Dependency 45·Confidence 90
Source evidence
“climate change could result in certain types of natural disasters occurring more frequently or with more intense effects, which could have a long-term impact on general economic conditions and the health benefits and pharmacy services industries in particular.”
Tariffs on pharmaceuticals
Cost Driver

Current and potential future tariffs are disclosed as a factor affecting pharmaceutical costs, a significant component of healthcare costs.

Relevance 60·Dependency 50·Confidence 88
Source evidence
“current and potential future tariffs and changes in discounts”
Artificial intelligence
Technology Dependency

AI failure to operate as intended and compliance with emerging AI laws/standards are disclosed risks; company also focuses on responsible AI adoption in talent development.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“failure of our information systems or technology, including artificial intelligence, to operate as intended”
Full company information
Latest profile, trading, valuation, and identifier data stored for ELV.
Share price
$398.25
Market cap
$86.37B
Exchange
NYSE
Currency
USD
CEO
Gail Koziara Boudreaux
Employees
96,615
IPO date
30/10/2001
Beta
0.696
Last dividend
$0.00
Day range
$394.31 – $400.86
52-week range
$274.84 – $436.24
1-day performance
-0.08%
1-year performance
44.90%
Current drawdown (1Y)
-8.71%
CIK
0001156039
CUSIP
036752103
ISIN
US0367521038
Created
07/12/2025, 03:46:06
Last update
24/09/2026, 22:03:43

Track Elevance Health Inc. with an AI analyst

See which prediction-market events move ELV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ELV from your Railway `news_articles` table.

Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)

Seeking Alpha • STOCK • 01/06/2026, 11:35:33

Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue?

Zacks Investment Research • STOCK • 22/05/2026, 14:32:34

Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript

Seeking Alpha • STOCK • 13/05/2026, 11:50:47

Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care

Business Wire • STOCK • 04/05/2026, 16:10:00

Elevance Health (NYSE: ELV) Stock Rises on Strong Q1 Earnings and Raised Profit Forecast

Market Data • Market Data • 23/04/2026, 23:17:04

ELV Beats Q1 Earnings Estimates on Rising Net Investment Income

Zacks Investment Research • STOCK • 22/04/2026, 16:11:15

Elevance Health, Inc. (ELV) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 22/04/2026, 16:10:36

Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates

Zacks Investment Research • STOCK • 22/04/2026, 10:16:07

Elevance raises annual profit forecast betting on cost control

Reuters • STOCK • 22/04/2026, 08:06:52

ELEVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Elevance Health, Inc. on Behalf of Elevance Stockholders and Encourages Investors to Contact the Firm

GlobeNewsWire • STOCK • 20/04/2026, 19:06:00

Will Health Benefits Weakness Drag Elevance's Q1 Earnings?

Zacks Investment Research • STOCK • 16/04/2026, 16:35:14

Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good

Seeking Alpha • STOCK • 07/04/2026, 12:32:49